We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01261156
Recruitment Status : Completed
First Posted : December 16, 2010
Last Update Posted : July 11, 2014
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to evaluate the effects of diltiazem on the pharmacokinetics (PK) and pharmacodynamics (PD) of E5555 and its metabolites in healthy subjects.

Condition or disease Intervention/treatment Phase
Healthy Subjects Drug: E5555 100 mg and diltiazem Drug: E5555 300 mg and diltiazem Phase 1

Detailed Description:
This is an open-label, 2-arm study to evaluate the effects of diltiazem given in conjunction with E5555 on the PK of diltiazem and its metabolites. This is a Phase 1 study of 24 healthy male and female subjects that will be conducted at a single site. The planned duration of treatment for each subject is approximately 15 days including 1 day in Treatment Period 1 and 14 days in Treatment Period 2.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Single-Sequence Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy Subjects
Study Start Date : October 2010
Primary Completion Date : December 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Study Arm 1 Drug: E5555 100 mg and diltiazem
E5555 single 100 mg oral dose in Treatment Period 1 Day 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
Experimental: Study Arm 2 Drug: E5555 300 mg and diltiazem
E5555 single 300 mg oral dose in Treatment Period 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.


Outcome Measures

Primary Outcome Measures :
  1. Evaluate the effects of diltiazem on the pharmacokinetics (PK ie. Cmax, Tmax, AUC and half-life) of E5555 and its known metabolites. [ Time Frame: 18 days ]
  2. Evaluate the effects of diltiazem on the thrombin- and thrombin receptor activating peptide (TRAP) -induced platelet aggregation of E5555 and its known metabolites [ Time Frame: 18 days ]

Secondary Outcome Measures :
  1. To evaluate the effects of co-adminstration of diltiazem and E5555 on the PK(ie. Cmax, Tmax, AUC and half-life) of diltiazem and its metabolites [ Time Frame: 18 days ]
  2. To evaluate effects of co-adminstration of diltiazem and E5555 on QTcF compared to E5555 alone [ Time Frame: 18 days ]
  3. To assess safety and tolerability of a single dose of E5555 when given alone or in combination with diltiazem by recording the number of all adverse events following drug administration [ Time Frame: 18 days ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion:

  • Provide written informed consent
  • Healthy, non-smoking, male or female subjects aged greater than or equal to 18 years to 55 years
  • Body mass index (BMI) greater than or equal to 18 and less than or equal to 32 kg/m2 at Screening
  • All females must have a negative serum beta human chorionic gonadotropin test result at Screening and Baseline. Females of child-bearing potential must agree to use a medically acceptable method of contraception commencing at least one menstrual cycle prior to starting study drug, throughout the entire study period and for 90 days after study drug discontinuation. The only subjects who will be exempt from this requirement are postmenopausal women or subjects who have been surgically sterilized or who are otherwise proven sterile.
  • Male subjects who are partners of women of childbearing potential and are not abstinent or have not undergone a successful vasectomy must use, or their partners must use, a highly effective method of contraception commencing at least one menstrual cycle prior to starting study drug, throughout the entire study period and for 90 days after study drug discontinuation.
  • Are willing and able to comply with all aspects of the protocol.

Exclusion:

  • A family history, past medical history or clinical signs or symptoms of a bleeding diathesis
  • History of any medical condition which will result in an increased risk of bleeding including but not limited to active or recurrent gastric ulcers, recent head trauma or surgery, severe hypertension, bacterial endocarditis etc
  • Subjects with a history of spontaneous gum bleeding or clinical signs or symptoms on physical exam
  • Clinically significant ocular disease or untreated visual or ocular symptoms
  • Clinically significant abnormal electrocardiograms ECGs prior to dosing (Screening or Baselines) including a QT interval corrected for heart rate using Fredericia's formula (QTcF) and/or Bazett's formula (QTcB) greater than 450 ms
  • Any history or past medical condition that will result in QTc prolongation or tachyarrhythmia such as Torsades de Points (includes hypokalemia, known family history of long QT syndrome, or any other known risk factors for Torsades de Points)
  • A platelet count less than 150,000 or greater than 390,000 per mL at Screening or Baseline Period 1
  • Abnormal (less than 80%) arachidonic acid induced platelet aggregation at Baseline Period 1
  • History of unexplained syncope, hepato-bliary disease, sinus bradycardia, heart blocks, sick-sinus syndrome, cardiogenic shock, heart failure, seizures, or chronic obstructive lung disease
  • Subjects with hypotension (less than 90 mm Hg systolic) and bradycardia (HR less than 40 beats per minute) or symptomatic bradycardia (HR less than 50 beats per minute)
  • Received blood, donated blood, or experienced significant blood loss within 60 days prior to check-in
  • Hypersensitivity to diltiazem or related compounds or ingredients in the formulation
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01261156


Locations
Netherlands
PRA International
Zuidlaren, Netherlands, 9471
Sponsors and Collaborators
Eisai Inc.
Investigators
Study Director: Chukwuemeka Okereke Eisai Limited
More Information

Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT01261156     History of Changes
Other Study ID Numbers: E5555-A001-022
First Posted: December 16, 2010    Key Record Dates
Last Update Posted: July 11, 2014
Last Verified: July 2014

Additional relevant MeSH terms:
Diltiazem
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents